Literature DB >> 15826607

Clofibrate and perfluorodecanoate both upregulate the expression of the pregnane X receptor but oppositely affect its ligand-dependent induction on cytochrome P450 3A23.

Yuzhong Ma1, Karuna Sachdeva, Jirong Liu, Xiulong Song, Yuxin Li, Dongfang Yang, Ruitang Deng, Clinton O Chichester, Bingfang Yan.   

Abstract

The pregnane X receptor (PXR) interacts with a vast array of structurally dissimilar chemicals and confers induction of several major types of drug metabolizing enzymes such as cytochrome P450s (CYP). We previously reported that the expression of PXR was markedly increased in rats treated with clofibrate and perfluorodecanoic acid (PFDA). The present study was undertaken to test the hypothesis that induced expression of PXR increases PXR ligand-dependent induction on CYP3A23. Rat hepatocytes were treated with clofibrate or PFDA individually, or along with PXR ligand pregnenolone 16alpha-carbonitrile (PCN), and the levels of PXR and CYP3A23 were determined by Western blots. Both clofibrate and PFDA markedly increased the expression of PXR with PFDA being more potent, and the induction was abolished by actinomycin D, an inhibitor for mRNA synthesis. As expected, PCN alone markedly induced the expression of CYP3A23. Interestingly, co-treatment with clofibrate enhanced the induction, whereas co-treatment with PFDA suppressed it. Clofibrate and PFDA represent multi-classes of chemicals called peroxisome proliferators including many therapeutic agents and industrial pollutants. The opposing effects of clofibrate and PFDA on the PCN-induced expression of CYP3A23 suggest that peroxisome proliferators likely increase the expression of PXR but differentially alter its ligand-dependent induction. The interaction between PXR inducer and ligand provides a novel mechanism on how functionally and structurally distinct chemicals cooperatively regulate the expression of xenobiotic-metabolizing enzymes and transporters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826607     DOI: 10.1016/j.bcp.2005.02.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3'-untranslated region and alters the expression of its target gene cytochrome P450 3A4.

Authors:  Thaveechai Vachirayonstien; Bingfang Yan
Journal:  Biochim Biophys Acta       Date:  2016-04-13

2.  Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor.

Authors:  Dongfang Yang; Jian Yang; Deshi Shi; Ruitang Deng; Bingfang Yan
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

3.  Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders.

Authors:  Nagendra Kumar Chaturvedi; Sanjay Kumar; Seema Negi; Rakesh K Tyagi
Journal:  Mol Cell Biochem       Date:  2010-09-10       Impact factor: 3.396

4.  Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.

Authors:  Jian Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2006-09-26       Impact factor: 4.849

5.  Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4α and up-regulating liver-enriched inhibitory protein.

Authors:  Thaveechai Vachirayonsti; Karen W Ho; Dongfang Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2015-01-22       Impact factor: 4.849

6.  Extracts of Immature Orange (Aurantii fructus immaturus) and Citrus Unshiu Peel (Citri unshiu pericarpium) Induce P-Glycoprotein and Cytochrome P450 3A4 Expression via Upregulation of Pregnane X Receptor.

Authors:  Naoto Okada; Aki Murakami; Shiori Urushizaki; Misa Matsuda; Kazuyoshi Kawazoe; Keisuke Ishizawa
Journal:  Front Pharmacol       Date:  2017-02-21       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.